Efficiency of controlled topical delivery of silver sulfadiazine in infected burn wounds.
The present study is designed to assess the potential benefits of controlled delivery of silver sulfadiazine from collagen scaffold (SSDM-CS) in infected deep partial thickness burn wounds in which epidermis is lost completely and the entire papillary dermis and most of the recticular layer of the dermis is lost. Infection induced by inoculating 10(7) colony forming units (cfu) of Pseudomonas aeruginosa caused significant increase in wound size (20%) till day 15, which decreased significantly from day 9 by SSDM-CS treatment, showing complete healing by day 27 (control > or = 37 days). Early subsidence of infection (<10(2) cfu, day 9) by SSDM-CS resulted in faster epidermal resurfacing and fibroplasia, whereas heavy microbial load (>10(7) cfu, day 9) in controls caused severe inflammatory cellular infiltration. Persistent infection triggered early expression of proinflammatory cytokines intereukin-6, intereukin 1-beta, and tumor necrosis factor-alpha, lasting until day 9, whereas cytokine level decreased in SSDM-CS-treated group by day 6. Infection exacerbated expression of active matrix metalloproteinases (MMPs)-2 and -9 in controls (day 15), while SSDM-CS positively modulated MMP-2 and -9 with faster decline in their levels (day 12). Inherent nature of the dressing to maintain drug level at equilibrium therapeutic concentration (51.2 microg/mL) for prolonged time (72 h), below systemic toxic limits (20 microg/dL, serum level), accelerated the magnitude and sequence of reparative events.
Shanmugasundaram
N
N
Biomaterials Division, Central Leather Research Institute - TICEL Biopark, Tharamani Road, Tharamani, Chennai 600 113, Tamil Nadu, India.
Uma
T S
TS
Ramyaa Lakshmi
T S
TS
Babu
Mary
M
D000287:Administration, Topical; D000818:Animals; D015153:Blotting, Western; D001835:Body Weight / Q000187:drug effects; D002056:Burns / Q000150:complications* / Q000188:drug therapy* / Q000201:enzymology / Q000473:pathology; D003094:Collagen / Q000378:metabolism; D016207:Cytokines / Q000378:metabolism; D003692:Delayed-Action Preparations; D003720:Densitometry; D004789:Enzyme Activation / Q000187:drug effects; D006595:Hexosamines / Q000378:metabolism; D018836:Inflammation Mediators / Q000378:metabolism; D020782:Matrix Metalloproteinases / Q000378:metabolism; D051381:Rats; D017208:Rats, Wistar; D012837:Silver Sulfadiazine / Q000008:administration & dosage* / Q000494:pharmacology / Q000627:therapeutic use*; D014945:Wound Healing / Q000187:drug effects; D014946:Wound Infection / Q000150:complications* / Q000188:drug therapy* / Q000201:enzymology / Q000473:pathology
D016207:Cytokines; D003692:Delayed-Action Preparations; D006595:Hexosamines; D018836:Inflammation Mediators; D003094:Collagen; D020782:Matrix Metalloproteinases; D012837:Silver Sulfadiazine